Immunotherapy-induced Leukoderma from treatment of melanoma with IL-2: A case report and a review of the literature

Acta Dermato-Venereologica

Volumn 95, Issue 2, 2015, Pages 197-200

  Gathings, Robert ^a   Lewallen, Robin ^b   Vitch, Gil Yosipo ^c  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST BAPTIST HEALTH   (United States)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

Autoimmunity; Immunotherapy; Leukoderma; Melanoma; Vitiligo

Indexed keywords

INTERLEUKIN 2; MELAN A; ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CANCER IMMUNOTHERAPY; CASE REPORT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG MEGADOSE; HUMAN; HUMAN CELL; LEUKODERMA; MALE; MELANOCYTE; MELANOMA; METASTATIC MELANOMA; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR IMMUNITY; ADVERSE EFFECTS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CANCER STAGING; CHEMICALLY INDUCED; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY; PIGMENTATION DISORDERS; SECONDARY; SKIN NEOPLASMS; SKIN PIGMENTATION; TREATMENT OUTCOME; VERY ELDERLY;

AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MALE; MELANOMA; NEOPLASM STAGING; PIGMENTATION DISORDERS; SKIN NEOPLASMS; SKIN PIGMENTATION; TREATMENT OUTCOME;

EID: 84928256596     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1897     Document Type: Article

References (16)

1. Cho EA, Lee MA, Kang H, Lee SD, Kim HO, Park YM. Vitiligo-like depigmentation associated with metastatic melanoma of an unknown origin. Ann Dermatol 2009; 1: 178–181.
2. Onsun N, Büyükbabani N, Ummetoğlu O, Cebeci F. Do we have to pay more attention to vitiligo patients? Peculiar histopathological features of primary cutaneous melanoma preceded by vitiligo. J Dermatol 2009; 36: 612–615.
3. Redondo P, Del Olmo J. Images in clinical medicine. Vitiligo and cutaneous melanoma. N Engl J Med 2008; 359: e3.
4. Wang JR, Yu KJ, Juan WH, Yang CH. Metastatic malignant melanoma associated with vitiligo-like depigmentation. Clin Exp Dermatol 2009; 34: 209–211.
5. Quaglino P, Marenco F, Osella-Abate S, Cappello N, Ortoncelli M, Salomone B, et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: Results from a single-institution hospital-based observational cohort study. Ann Oncol 2010; 21: 409–414.
6. Minkis K, Garden BC, Wu S, Pulitzer MP, Lacouture ME. The risk of rash associated with Ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis. J Am Acad Dermatol 2013; 69: e121–e128.
7. Alonso-Castro L, Ríos-Buceta L, Vano-Galvan S, Moreno C, Soria-Rivas A, Jaén P. Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma. J Am Acad Dermatol 2013; 69: e28–e29.
8. Byrne KT, Turk MJ. New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget 2011; 2: 684–694.
9. Janas ML, Groves P, Kienzle N, Kelso A. IL-2 regulates perforin and granzyme gene expression in CD8+ T cells independently of its effects on survival and proliferation. J Immunol 2005; 175: 8003–8010.
10. Banaszynski M, Kolesar JM. Vemurafenib and ipilimumab: new agents for metastatic melanoma. Am J Health Syst Pharm 2013; 70: 1205–1210.
11. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001; 19: 3477–3482.
12. Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cellmediated vitiligo. J Exp Med 2000; 192: 1637–1644.
13. Byrne KT, Côté AL, Zhang P, Steinberg SM, Guo Y, Allie R, et al. Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma. J Clin Invest 2011; 121: 1797–1809.
14. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 1996; 19: 81–84.
15. Teulings HE1, Overkamp M, Ceylan E, Nieuweboer-Krobotova L, Bos JD, Nijsten T, et al. Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners. Br J Dermatol 2013; 168: 162–171.
16. Hartmann A, Bedenk C, Keikavoussi P, Becker JC, Hamm H, Bröcker EB. Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features. J Dtsch Dermatol Ges 2008; 6: 1053–1059.